International adaptations of NCCN clinical practice guidelines in oncology

Robert W. Carlson*, Jonathan K. Larsen, Joan McClure, C. Lyn Fitzgerald, Alan P. Venook, Al B Benson III, Benjamin O. Anderson

*Corresponding author for this work

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are evidence- and consensus-based clinical practice guidelines addressing malignancies that affect more than 97% of all patients with cancer in the United States. The NCCN Guidelines are used extensively in the United States and globally. Use of the guidelines outside the United States has driven the need to adapt the guidelines based on local, regional, or national resources. The NCCN Guidelines Panels created, vetted, and continually update the NCCN Guidelines based on published scientific data on cancer detection, diagnosis, and treatment efficacy. The guidelines are developed within the context of commonly available resources, methods of payment, societal and cultural expectations, and governmental regulations as they exist in the United States. Although many of the cancer management recommendations contained in the NCCN Guidelines apply broadly from a global perspective, not all do. Disparities in availability and access to health care exist among countries, within countries, and among different social groups in the same country, especially regarding resources for cancer prevention, early detection, and treatment. In addition, different drug approval and payment processes result in regional variation in availability of and access to cancer treatment, especially highly expensive agents and radiation therapy. Differences in cancer risk, predictive biomarker expression, and pharmacogenetics exist across ethnic and racial groups, and therefore across geographic locations. Cultural and societal expectations and requirements may also require modification of NCCN Guidelines for use outside the United States. This article describes the adaptation process, using the recent Latin American adaptation of the 2013 NCCN Guidelines for Colorectal Cancer as an example.

Original languageEnglish (US)
Pages (from-to)643-648
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Practice Guidelines
Guidelines
Neoplasms
Drug Approval
Geographic Locations
Health Services Accessibility
Pharmacogenetics
Early Detection of Cancer
Ethnic Groups
Colorectal Neoplasms
Radiotherapy
Biomarkers
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Carlson, Robert W. ; Larsen, Jonathan K. ; McClure, Joan ; Fitzgerald, C. Lyn ; Venook, Alan P. ; Benson III, Al B ; Anderson, Benjamin O. / International adaptations of NCCN clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2014 ; Vol. 12, No. 5. pp. 643-648.
@article{5217f01c5b4e48cf973c92783b06755d,
title = "International adaptations of NCCN clinical practice guidelines in oncology",
abstract = "The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are evidence- and consensus-based clinical practice guidelines addressing malignancies that affect more than 97{\%} of all patients with cancer in the United States. The NCCN Guidelines are used extensively in the United States and globally. Use of the guidelines outside the United States has driven the need to adapt the guidelines based on local, regional, or national resources. The NCCN Guidelines Panels created, vetted, and continually update the NCCN Guidelines based on published scientific data on cancer detection, diagnosis, and treatment efficacy. The guidelines are developed within the context of commonly available resources, methods of payment, societal and cultural expectations, and governmental regulations as they exist in the United States. Although many of the cancer management recommendations contained in the NCCN Guidelines apply broadly from a global perspective, not all do. Disparities in availability and access to health care exist among countries, within countries, and among different social groups in the same country, especially regarding resources for cancer prevention, early detection, and treatment. In addition, different drug approval and payment processes result in regional variation in availability of and access to cancer treatment, especially highly expensive agents and radiation therapy. Differences in cancer risk, predictive biomarker expression, and pharmacogenetics exist across ethnic and racial groups, and therefore across geographic locations. Cultural and societal expectations and requirements may also require modification of NCCN Guidelines for use outside the United States. This article describes the adaptation process, using the recent Latin American adaptation of the 2013 NCCN Guidelines for Colorectal Cancer as an example.",
author = "Carlson, {Robert W.} and Larsen, {Jonathan K.} and Joan McClure and Fitzgerald, {C. Lyn} and Venook, {Alan P.} and {Benson III}, {Al B} and Anderson, {Benjamin O.}",
year = "2014",
month = "1",
day = "1",
doi = "10.6004/jnccn.2014.0068",
language = "English (US)",
volume = "12",
pages = "643--648",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

International adaptations of NCCN clinical practice guidelines in oncology. / Carlson, Robert W.; Larsen, Jonathan K.; McClure, Joan; Fitzgerald, C. Lyn; Venook, Alan P.; Benson III, Al B; Anderson, Benjamin O.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 12, No. 5, 01.01.2014, p. 643-648.

Research output: Contribution to journalArticle

TY - JOUR

T1 - International adaptations of NCCN clinical practice guidelines in oncology

AU - Carlson, Robert W.

AU - Larsen, Jonathan K.

AU - McClure, Joan

AU - Fitzgerald, C. Lyn

AU - Venook, Alan P.

AU - Benson III, Al B

AU - Anderson, Benjamin O.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are evidence- and consensus-based clinical practice guidelines addressing malignancies that affect more than 97% of all patients with cancer in the United States. The NCCN Guidelines are used extensively in the United States and globally. Use of the guidelines outside the United States has driven the need to adapt the guidelines based on local, regional, or national resources. The NCCN Guidelines Panels created, vetted, and continually update the NCCN Guidelines based on published scientific data on cancer detection, diagnosis, and treatment efficacy. The guidelines are developed within the context of commonly available resources, methods of payment, societal and cultural expectations, and governmental regulations as they exist in the United States. Although many of the cancer management recommendations contained in the NCCN Guidelines apply broadly from a global perspective, not all do. Disparities in availability and access to health care exist among countries, within countries, and among different social groups in the same country, especially regarding resources for cancer prevention, early detection, and treatment. In addition, different drug approval and payment processes result in regional variation in availability of and access to cancer treatment, especially highly expensive agents and radiation therapy. Differences in cancer risk, predictive biomarker expression, and pharmacogenetics exist across ethnic and racial groups, and therefore across geographic locations. Cultural and societal expectations and requirements may also require modification of NCCN Guidelines for use outside the United States. This article describes the adaptation process, using the recent Latin American adaptation of the 2013 NCCN Guidelines for Colorectal Cancer as an example.

AB - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are evidence- and consensus-based clinical practice guidelines addressing malignancies that affect more than 97% of all patients with cancer in the United States. The NCCN Guidelines are used extensively in the United States and globally. Use of the guidelines outside the United States has driven the need to adapt the guidelines based on local, regional, or national resources. The NCCN Guidelines Panels created, vetted, and continually update the NCCN Guidelines based on published scientific data on cancer detection, diagnosis, and treatment efficacy. The guidelines are developed within the context of commonly available resources, methods of payment, societal and cultural expectations, and governmental regulations as they exist in the United States. Although many of the cancer management recommendations contained in the NCCN Guidelines apply broadly from a global perspective, not all do. Disparities in availability and access to health care exist among countries, within countries, and among different social groups in the same country, especially regarding resources for cancer prevention, early detection, and treatment. In addition, different drug approval and payment processes result in regional variation in availability of and access to cancer treatment, especially highly expensive agents and radiation therapy. Differences in cancer risk, predictive biomarker expression, and pharmacogenetics exist across ethnic and racial groups, and therefore across geographic locations. Cultural and societal expectations and requirements may also require modification of NCCN Guidelines for use outside the United States. This article describes the adaptation process, using the recent Latin American adaptation of the 2013 NCCN Guidelines for Colorectal Cancer as an example.

UR - http://www.scopus.com/inward/record.url?scp=84900432125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900432125&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0068

DO - 10.6004/jnccn.2014.0068

M3 - Article

C2 - 24812133

AN - SCOPUS:84900432125

VL - 12

SP - 643

EP - 648

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 5

ER -